824 filings
Page 4 of 42
8-K
te5a rz29siy7io
19 Apr 23
Entry into a Material Definitive Agreement
5:25pm
CORRESP
0dtb22d
19 Apr 23
Correspondence with SEC
12:00am
8-K
d8j fx7i2zak
14 Apr 23
Other Events
8:33am
8-K
t5na 1vink
10 Apr 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
7:30am
UPLOAD
zlagjkfwrh34nca6ah
7 Apr 23
Letter from SEC
12:00am
8-K
qkcpr
24 Feb 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:06pm
8-K
az6k1t gskgt9bl
14 Feb 23
Soligenix Receives Refusal to File Letter from U.S. FDA for HyBryte™ New Drug Application in the Treatment of Cutaneous T-Cell Lymphoma
7:46am
8-K
z9dpffh34 2ebet8y0
9 Feb 23
Soligenix Announces Reverse Stock Split
7:45am
DEFA14A
ntyxp9fg eu8th89zto3
11 Jan 23
Additional proxy soliciting materials
8:02am
8-K
tzlk1v1p8tx5
11 Jan 23
Other Events
8:00am
8-K
booeil
27 Dec 22
Soligenix Announces Distribution of Series D Preferred Stock to Holders of its Common Stock
4:25pm
8-A12G
m93pw9a2
27 Dec 22
Registration of securities
4:05pm
8-K
tbu3mc9e1zd4al
23 Dec 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:05pm
8-K
obh5h8ovxhd 089
19 Dec 22
Other Events
8:00am
8-K
n4x8qd
15 Dec 22
Soligenix Announces Submission of New Drug Application to the FDA for HyBryte™ in the Treatment of Cutaneous T-cell Lymphoma
8:14am
8-K
op4p14ksst7wz38wi4h
18 Nov 22
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:45pm